www.synconaltd.com
Full Year Results
6 July 2017
Full Year Results 6 July 2017 www.synconaltd.com Disclaimer By - - PowerPoint PPT Presentation
Full Year Results 6 July 2017 www.synconaltd.com Disclaimer By accepting receipt of this presentation you represent, warrant and agree that you will not attempt to reproduce or transmit the contents (in whole or part), directly or indirectly, of
www.synconaltd.com
6 July 2017
2
By accepting receipt of this presentation you represent, warrant and agree that you will not attempt to reproduce or transmit the contents (in whole or part), directly or indirectly, of this presentation by any means. For the purposes
contents of this presentation must be kept confidential by attendees at such presentation and must not be reproduced, printed, distributed, passed on directly or indirectly, to any person or otherwise. This presentation is published solely for informational purposes and shall not to be construed as giving investment, legal or tax advice. It has no regard to the specific investment objectives, financial situation or particular needs
is or will be accepted by Syncona Ltd, its affiliates, agents, directors, managers or any of its advisers as to the accuracy, correctness, fairness or completeness of, the information or opinions contained in this presentation. Syncona Ltd and its affiliates, agents, directors, managers and advisers, accept no liability whatsoever for any loss or damage howsoever arising from any use of this presentation or its content or otherwise arising in connection therewith. The information and opinions contained in the presentation do not purport to be comprehensive, are provided as at the date of the document and are subject to change without notice. Neither Syncona Ltd nor any other person are under any obligation to update or keep current the information contained herein. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any investment decision or contract therefor. This presentation has not been approved by any supervisory authority and no regulatory approvals have been obtained. This presentation may not be used for and does not constitute an offer to sell, or a solicitation of any offer,
The presentation contains certain “forward-looking statements” regarding the belief or current expectations of Syncona Ltd and representatives of its manager or advisor about the financial condition, results of operations and business of Syncona Ltd. Such forward-looking statements are not guarantees of future performance. Rather, they speak only as of the date of this presentation, are based on current views and assumptions and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Syncona Ltd and are difficult to predict, that may cause the actual results, performance, achievements or developments of Syncona Ltd, its current or future investments or the industry in which it operates to differ materially from any future results, performance, achievements or developments expressed or implied from the forward-looking statements. The target return and target dividend of Syncona Ltd referred to in this presentation are based on performance projections produced by the manager or advisor to the best of their knowledge and belief. The potential return, valuation and dividend figures quoted in this presentation for Syncona Ltd and any investment opportunities are targets, estimates or illustrations only (which may or may not include figures which are based over the long-term on the performance projections of the investment strategy) and therefore are subject to change. There is no guarantee that such target return and target dividend of Syncona Ltd can be achieved and past or targeted performance is no indication of current or future performance or results. There can be no assurance that the strategy described herein will meet its objectives generally, or avoid losses. This communication is only addressed to, and directed at, persons in member states of the European Economic Area who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive ("Qualified Investors"). For the purposes of this provision, the expression "Prospectus Directive" means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each member state of the European Economic Area which has implemented the Prospectus Directive. In addition, in the United Kingdom, this communication is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments who fall within the definition of "investment professional" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"),
communicated (all such persons together being referred to as “relevant persons”). Any investment or investment activity to which this communication relates is available only to and will only be engaged in with such persons. This communication must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons, and (ii) in any member state of the relevant European Economic Area other than the United Kingdom, by persons who are not Qualified Investors. This is not an offer for sale of securities, nor a solicitation to purchase or subscribe for securities, in any jurisdiction. The securities of the Company referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ( the “Securities Act”) , or the U.S. Investment Company Act of 1940, as amended (the “Investment Company Act”) or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, transferred or delivered, directly or indirectly, within the United States, except pursuant to exemptions from, or in a transaction not subject to, the registration requirements of the Securities Act and the Investment Company Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. No money, securities or other consideration is being solicited and, if sent in response to the information contained herein, will not be accepted. Subject to limited exceptions, neither this presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the United States, its territories or possessions. Any failure to comply with this restriction may constitute a violation of U.S. securities laws. This presentation is also not for publication, release or distribution, directly or indirectly, in nor should it be taken or transmitted, directly or indirectly into, the United States, Canada, Australia, South Africa, Switzerland or Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. The distribution of this presentation outside the United Kingdom may be restricted by law and therefore persons outside the United Kingdom into whose possession this presentation comes should inform themselves about and observe any such restrictions as to the distribution of this presentation. Except as provided in this disclaimer, neither this presentation, nor any copy of it, may be taken, transmitted or distributed, directly or indirectly, in or into any jurisdiction other than the United Kingdom. Recipients represent and warrant that (i) they are not based in a jurisdiction where possession or distribution of this presentation contravenes any securities legislation or any other applicable laws, (ii) they are not resident in a territory outside the United Kingdom, (iii) they are not acting as nominee or agent for any person or persons who by virtue of their residence or incorporation would not be entitled to subscribe for the shares or securities described herein, (iv) they have not taken any action which will or may result in the Company or its subsidiaries or any of their respective directors, officers, employees or agents acting in breach of any regulatory or legal requirement. Recipients of this presentation (and any related materials) should not base any behaviour in relation to qualifying investments or relevant products (as defined in the Financial Services and Markets Act 2000 ("FSMA")), which would amount to "market abuse" for the purposes of FSMA, on the information in this presentation (and any related materials) until after the information has been made generally available. Nor should the recipient use the information in this presentation (and any related materials) in any way which would constitute market abuse. Prior to making any potential investment, potential investors should, at their own expense, consult with their own legal, investment, accounting, regulatory, tax and other advisors to determine the consequences of the potential investment opportunity described herein and to arrive at an independent evaluation of such potential investment opportunity.
Successful completion of the acquisition of Syncona Partners by BACIT in December 2016 – Investment policy expanded – Purchase of life science portfolio with investment team from the Wellcome Trust Strong start to life as a combined business – Net assets at year end of £895.2m,136.0p per share, total return 12.5%1 – Dividend of 2.3p declared Significant momentum in life science portfolio – Value uplift of £24.9m (12.4%) to £226.6m since December acquisition – Encouraging progress across the portfolio and strong pipeline of opportunities Life Science progress underpinned by strong funds portfolio performance – Funds portfolio valued at £582.4m, net total return of 11.8% – Transition of the portfolio to focus on more liquid assets has begun Charitable donations of £4.75m; 50% to The Institute of Cancer Research
Evolution to invest in and build global leaders in life science
3
1 Including 2.2p dividend paid in August 2016
4
Life science investments underpinned by evergreen long-term funding
Our funds portfolio seeks to deliver attractive risk- adjusted returns through investing in a range of leading long only and alternative funds, across a variety of strategies and geographies. We specialise in creating, investing in and building companies that have the potential to transform the delivery of healthcare in their respective markets.
Funds Portfolio
Life Science Portfolio
Total
Cash
Life science
Funds
All figures as at 31 March 2017.
Three key strategic pillars
5
Delivering superior shareholder returns by maximising the value available from the successful commercialisation
transformational treatments to patients. Disciplined approach to capital allocation
1
⎼ Evergreen long-term funding base ⎼ Funds portfolio invests in leading long-
⎼ Provides a productively deployed capital base available to invest in compelling life science investment opportunities at the right time ⎼ Recycle capital back into the portfolio as investments are realised
Focused and selective investment strategy
2
⎼ Multi-disciplinary investment team with proven track record ⎼ High conviction approach to building a selective portfolio of high quality healthcare businesses in truly innovative areas of science ⎼ Underpinned by leading funds portfolio with high emphasis on containing volatility
Building globally competitive healthcare businesses
3
⎼ Partnership approach with the best, brightest and most ambitious minds in life science ⎼ Hands-on approach to supporting businesses to grow and succeed over the long term. ⎼ Strategy of maintaining significant
marketed product to maximise exposure to upside
£5.0m 78% £34.2m 55% £2.8m 66% £18.0m 74% £31.2m 37% £5.2m 12% £108.4m 90% Marketed products Clinical trials Pre-clinical trials
Invested in specialist and innovative areas of healthcare across the development cycle
6
Best ideas
Syncona investment point Developing Maturing Established
£21.8m 64%
CRT Pioneer Fund:
Syncona valuation Syncona ownership stake
Speciality area: Advanced Diagnostics Source:
First Syncona-founded company to reach on- market status – Axumin successfully launched – US FDA approval in May 2016, 18 months ahead of plan – Commenced sales August 2016, early sales data very encouraging: – c200 units sold during Q4 2016 soft launch; increased to c800 units in Q1 2017 Achieved key milestone towards securing sales approval in European Union – Positive opinion from Committee for Medicinal Products for Human Use (CHMP) received in March – Formal approval to commence EU sales received from EMA post year end in May
Molecular imaging agent company addressing areas of high unmet need
7
Value – Significant value uplift from £83.5 million to £108.4m, 12.1% of total NAV Next steps – Continue Axumin’s positive commercial trajectory in the US – Commence sales of Axumin in Europe – Progress development of Axumin for additional indications
Established
Speciality area: Gene Therapy Source:
Significant progress delivered – Significantly progressed phase II trials for lead indication, choroideremia – Commenced clinical trial in second indication
– Strengthened management team Value: post year end new investment to drive long term success – US$45m Series C investment round in June – Syncona investment US$12.5 million, retaining a 46% stake – Joined by new leading international institutional investors – Syncona’s investment written up by £20.3m (3.1p per share) to £69.7m
Building a global leader in gene therapy for inherited retinal diseases
8
Next steps – Initiate pivotal phase III trial in choroideremia – Progress phase I/II trials for X-Linked Retinitis Pigmentosa
Maturing
8
Speciality area: Cell Therapy Source:
Establishing a leading position in T cell product manufacture and delivery – Secured suite at Cell and Gene Therapy Catapult manufacturing centre in Stevenage – State of the art site with government backing to support growth in cell and gene therapy Experienced and commercially-driven management team – Significantly strengthened team including appointment of Chief Medical Officer
Syncona-founded leader in innovative precision T cell therapies
9
Next steps – Commence three clinical trials in multiple myeloma, Non-Hodgkin’s lymphoma and T cell lymphoma
Maturing
Earlier stage businesses progressing in line with plans
10
Company Vision Milestones achieved Next steps
– Developing innovative liver-
directed gene therapies
– Lead programme in
Haemophilia B, a rare disorder which currently requires lifelong treatment
– Progressed pre-clinical development
for haemophilia B programme
– Commissioned manufacturing process
development capability
– Strengthened management team in
finance, operations and IP
– Commence clinical
development of haemophilia B
– Syncona’s second retinal gene
therapy business, operating in an area of breakthrough scientific advances
– Built out management team and
company infrastructure
– ‘Launch’ of business
within 12 months
– Utilising cutting edge advances
in DNA sequencing and immunotherapy, initially focused on non small cell lung cancer, where no cures exist
– Formally founded with seed financing
from Syncona
– Chris Ashton (Syncona) appointed CEO – Head corporate office and laboratory
established
– Initiate clinical
programme for lead indication by calendar year 2020
– Pioneering in the field of
epigenetics, utilising proprietary technology in partnership with leading companies to develop improved diagnostic tools
– Licenced fundamental DNA methylation
IP from Boston Children’s Hospital
– Established Scientific Advisory Board – Developing
technology and building out management and infrastructure
Developing
www.synconaltd.com
John Bradshaw, CFO Syncona Investment Management Limited
Wellcome Trust Cancer Research UK Other new shareholders
– Acquisition of life science investment portfolio from the Wellcome Trust and Cancer Research UK – Investment policy expanded to enable investment in life science businesses – £357.1m of shares issued at a price
– Including £169.6m of new capital raised from new and existing investors – 1.35% premium to NAV at the time
– Life science investment management team and funds portfolio team combined – Name changed from BACIT to Syncona
Shift to focus on investing in life science
12
Combination of two leading teams to create Syncona Limited
Equity issue
New capital raised Purchase of portfolio from the Wellcome Trust Purchase of CRT Pioneer Fund from Cancer Research UK
Strong 2017 performance driven by funds and life science portfolios
13
123p 3p 9p 4p
136p
100 105 110 115 120 125 130 135 140 145
Opening NAV per share Capital raising Funds portfolio gains Life sciences gains Dividend & Donation Costs Closing NAV
Progression in portfolio valuation driven by Blue Earth Diagnostics
14
Company Valuation (£m) Valuation basis Movement in the period1 % of NAV
108.4 DCF £24.9m 12.1% 34.2 PRI – 3.8% 31.2 PRI – 3.5% 18.0 Cost – 2.0% 2.8 Cost – 0.3% 5.0 Cost – 0.6% 5.2 PRI – 0.6%
CRT Pioneer Fund
21.8 Third-party – 2.4% Total 226.6 –
Life science portfolio at 31 March 2017
1 in the period since acquisition.
– Blue Earth Diagnostics written up by £24.9m (3.8p)
– Successful commercial launch of Axumin in the US; CHMP recommendation in Europe, with subsequent EMA approval – Valued on a risk adjusted DCF basis
– Post year end write up of Nightstar following completion of Series C financing round
– US$12.5m (£9.8m) investment from Syncona in US$45m round – £20.3m (3.1p) write-up of investment to £69.7m
Established company Maturing company Developing company
Funds portfolio
– Third party basis
Life science portfolio
– Updates outside the cycle driven by new investment rounds or following material new information – Developing and maturing investments
– At either Cost or Price of Recent Investment where a credible arms-length third party transaction has taken place
– Established investments
– Once near or at on-market stage valued
– CRT Pioneer Fund
– Quarterly valuation based on an adjusted third party basis A robust policy and conservative approach
15
Portfolio valuation basis
Third party Discounted Cash Flow Price of Recent Investment Cost
A strong capital base with significant cash balances and liquidity
16
Cash resources of £86.3m at year end
– Liquidity in the funds portfolio drawn down as new and follow-on investments in life science are made – Uncalled commitments of £50.1m to life science portfolio
– Linked to achievement of milestones
– Expect to invest c.£75m - £150m in next 12 months into life science portfolio
– £26.2m invested since the year end
– Nightstar Series C, Autolus and Freeline
– Near term visibility on a further £18.0m of follow-on investments
Liquidity profile
Cash Within 1 month 1-3 months 3-12 months Greater than 12 months
Efficient allocation approach focused on maximising shareholder value
17
– Weighting to life sciences will increase – Disciplined and rigorous capital allocation embedded in the life science investment process
– Follow-on investments linked to successful delivery of commercial and development milestones – New investments must offer compelling return potential against existing portfolio
– Recycle capital back into funds portfolio as life science investment are realised
– Productively deployed capital base
Total
Cash
Life science
Funds
All figures as at 31 March 2017.
Deep pool of evergreen funding enables a long term approach
www.synconaltd.com
Arabella Cecil, CIO, Funds
– Invested across a broad range of strategies – A portfolio that generates absolute returns through the cycle – Limited sensitivity to market dislocations – 60% weighting to hedge funds – Remaining portfolio weighed to funds with a long bias – Foreign exchange – Substantially all euro share classes hedged – 21% of exposure to US$ share classes unhedged – Captured 83% of FTSE All-Share (TR) since inception Seeking to deliver attractive risk-adjusted returns to underpin the growth of life science
19
Delivery of robust, low volatility returns through a diverse range of funds
0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50%
10/1/12 2/1/13 6/1/13 10/1/13 2/1/14 6/1/14 10/1/14 2/1/15 6/1/15 10/1/15 2/1/16 6/1/16 10/1/16 2/1/17
NAV return since listing in October 2012
NAV Return FTAll Share TR (£) HFRI Fund of funds Index
Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017
£582.4m invested in 37 funds across 25 managers
Strong performance across the portfolio; positive tailwind of foreign exchange
20
Equity hedge funds £222m – 38% of the portfolio – 12 managers, broadly diversified across major economies – Underlying managers with long track records generating ‘alpha’ and uncorrelated returns
14% total return in the year – Managers successfully pre-empted market dislocations and volatility
Equity hedge funds Equity funds Fixed income and credit Global macro Other strategies Commodity funds Equity funds £140m – 24% of the portfolio – Small number of managers that have outperformed respective benchmarks – Weighted towards Japan and UK
32% total return in the year – Managers outperformed benchmarks, in some cases significantly
Seek to limit the sensitivity to market dislocations
21
Fixed income and credit £88m – 15% of the portfolio – Fixed income – inflation linked – Credit – Strong stable returns to date – Three credit specialists with strong track records of exploiting anomalies in the market
Managers successfully navigated volatility in the European markets – Spreads tightened over the year, providing tailwind for long bias elements
Equity hedge funds Equity funds Fixed income and credit Global macro Other strategies Commodity funds Global macro £76.8m – 13% of the portfolio – Asymmetric returns – Focus on exploiting pricing bubbles across asset classes
Positive performance both on absolute and relative basis – Active backdrop proved challenging to monetise
Seek to limit the sensitivity to market dislocations
22
Other strategies £34m – 6% of the portfolio – Longer dated investments – private equity, infrastructure and credit
Private equity and infrastructure assets beginning to generate strong returns – Driven by positive performance of the underlying companies and realisations
Equity hedge funds Equity funds Fixed income and credit Global macro Other strategies Commodity funds Commodity funds £21m – 3% of the portfolio – Energy, soft and industrial commodities – long/short funds
Challenging year after three years of very strong and uncorrelated returns
Transitioning to more liquid assets to underpin the life science portfolio
23
– Transitioning to more liquid assets – Even greater emphasis on containing volatility – Broader investment mandate with ability to invest with managers on a net basis – Less appetite for long-bias assets – Evolving to focus on 15 - 20 leading managers across a more concentrated range of strategies
Total
Cash
Life science
Funds
All figures as at 31 March 2017.
Evolving to reflect expansion of investment policy
An evolving landscape in 2017
24
Positives
genuine economic recovery
Negatives
Portfolio positioning
markets, and have technical support
and short
hedged
www.synconaltd.com
Martin Murphy, CEO
Maintaining significant stakes in our portfolio businesses through to on-market patient treatment
Taking a unique partnership approach to building successful, sustainable and globally leading healthcare businesses
Dramatic efficacy for patients in areas
Building global leaders in life science to drive transformational treatments for patients
26
Transformational treatments for patients
Our three core principles
On market
27
Seeking to build and capture greater value through the cycle.
Clinical trials Best ideas
Value Development Milestones
Seeking high quality opportunities with flexibility on point of entry 1
Hands-on approach to investment supports long-term value creation
28
Long-term commitment – Clear focus on how best to support the development of successful on-market treatments – Alignment across shareholders and management Hands-on approach – Deep involvement and close collaboration with portfolio management teams – Bringing the operational, strategic, industrial and commercial discipline to small businesses Expert support – Blend of scientific and commercial expertise – Deep knowledge in core focus areas – Core capabilities throughout life cycle from company creation to market launch and beyond
2
6
6 out of 7 current portfolio companies founded by Syncona.
10
10 board seats including 6 as chair.
6
6 companies where we have held management and operational roles including 5 as CEO.
7
7 companies where we have appointed leading management teams.
Bringing industrial discipline through the development cycle
29
Company Creation
– Axumin asset selected from
a portfolio of diagnostics
– GE License agreement – Team recruitment – Competitive environment
analysis & market scoping
– Business plan creation; forward
planning on manufacturing, supply chain, logistics
– Clinical development strategy – IP strategy – Pricing strategy – Distribution contract analysis
and negotiation
– Team expansion – Industrial discipline: – Operational, commercial
& financing plans
– Analytics & modelling,
customer and pricing segmentation
– Milestone development – Launch preparation – Launch execution – Aligning Siemens/ BED
salesforce
– In-market strategy – Business prioritisation – Reporting and performance
analysis practices
– Quality control – Supply Chain – Sales and marketing team
recruitment and training
– Business development: pipeline
and partnership strategy
Commercial Launch and Beyond Technical Validation
2
30
Characteristic Guiding principles High unmet medical need
– How severe is the disease? – Is it manageable with existing treatments? – Would a treatment be attractive to patients and insurers?
Truly innovative areas
– Is the proposed treatment in a format that makes sense for these patients? – Can we establish a leadership position in the field? – Is the IP protectable?
Potential for dramatic efficacy
– Does the proposed treatment have a strong biological rationale? – Would addressing that biology have a significant clinical impact? – Is that clinical impact going to address what patients care about most?
Focused on niche, high innovation areas with potential for dramatic efficacy
Enabling transformational treatments for patients
3 Gene Therapy Cell Therapy Advanced Diagnostics
– New areas such as cell therapy, gene therapy and DNA sequencing are offering the potential to address areas of high unmet need and challenge traditional operating models – Opportunities to revolutionise healthcare, disrupt established business models and vastly improve treatments for patients – Syncona has developed deep capabilities in technologies such as gene therapy, cell therapy and advanced diagnostics Syncona has established a leadership position in a new wave of technologies
31
“First Wave’’
1950s
Small Molecule drugs, market dominated by large pharmaceutical companies.
“Second Wave’’
1990s
Large Molecule (anti-body therapies and enzyme replacement therapies) market dominated by pharma and US biotech companies.
The “Third Wave’’
Today
Advanced Biologics and Diagnostics in areas such as gene therapy, cell therapy and DNA
well defined patient populations. Opportunity for market innovation and disruption.
1 3
Anticipate strong strategic progress in life science portfolio – Commence EU sales for Axumin in Blue Earth Diagnostics – Commence pivotal phase III trial for choroideremia in Nightstar – Commence three clinical trials in Autolus Strong pipeline of new life science investment
– c.£75 – £150m in new and existing investments – Range of potential investments being reviewed for scientific and strategic fit
Positive outlook for first year as a combined business and clear long term vision
32
Funds portfolio well positioned – Transitioning to more liquid assets – Focus on containing volatility – Good pipeline of potential new investments.
A Clear Long-Term Vision
⎻ Deliver transformational treatments to patients ⎻ Build global leaders in innovative areas of healthcare ⎻ Deliver at least 3-5 successful, sustainable market product companies ⎻ Build a focused portfolio of up to 20 investments in the best life science
⎻ Deliver superior returns to shareholders – 15% net IRR through the cycle
Long-term capital base
⎻ Productively deployed ⎻ Ability to invest through the cycle Maximising value by building global leaders in healthcare
33
1 2 3
Focus
⎻ Leadership position in highly innovative areas of healthcare
4 5 6
Strong partnership approach
⎻ Creating successful, scalable standalone businesses
Expertise
⎻ Leading, multi-disciplinary investment team with proven track record
Premium heritage and access
⎻ High quality global networks ⎻ Aligned with The Wellcome Trust and Cancer Research UK
Selective
⎻ Focused portfolio ⎻ High conviction investments
www.synconaltd.com
35
Martin Murphy, CEO
⎻ MVM Life Science Partners ⎻ 3i Group ⎻ McKinsey & Company ⎻ PhD Biochemistry, University
Iraj Ali
⎻ Co-founder of McKinsey launch practice and leader of speciality pharma practice ⎻ PhD Biochemistry, University
Chris Ashton
⎻ 30 years experience in Biotech ⎻ Serial CEO: Pulmagen, Argenta, Orchid ⎻ PhD Chemistry, UMIST ⎻ Currently CEO of portfolio company Achilles
Chris Hollowood, CIO
⎻ Apposite Capital ⎻ Bioscience Managers ⎻ PhD Organic Chemistry, University of Cambridge
Dominic Schmidt
⎻ L.E.K. Consulting ⎻ PhD Oncology, University of Cambridge
Edward Hodgkin
⎻ CEO of Biotica Technology ⎻ President & Chief Business Officer of BrainCells ⎻ DPhil Chemistry, University
⎻ Served as CEO of Autolus
Elisa Petris
⎻ Michel Dyens, with focus on healthcare ⎻ L.E.K. Consulting ⎻ PhD Molecular Biology, Imperial College
John Bradshaw, CFO
⎻ Chartered accountant (ICAEW) with Arthur Andersen ⎻ Extensive life science sector experience
Nicole Padden
⎻ Chartered accountant (ICAEW) ⎻ CMC background at GSK ⎻ PhD Biotechnology, KCL ⎻ MBA, Warwick Business School
Alex Hamilton
⎻ Jefferies Healthcare Investment Banking ⎻ PhD Immunology, University
Hitesh Thakrar
⎻ Portfolio manager Abu Dhabi Investment Authority ⎻ MBA Cranfield school of management ⎻ BSc Chemistry, KCL
Magda Jonikas
⎻ Associate Partner at McKinsey & Co specialising in pharmaceuticals ⎻ PhD Bioengineering, Stanford University ⎻ Postdoctoral fellow, Harvard Medical School.
A team with a track record of creating value in the life science sector
Clear investment strategy drives a disciplined investment approach
36
3 2 1 Source
– Unconstrained: ability to pick the best science – Drawing on premium network and heritage
Investment stage
– Flexible to point
development cycle – Guided by quality, strategic fit
Deep diligence
– Rigorous approach to verify scientific and commercial potential – Development of deep knowledge in investment areas
Location
– Core focus UK and Europe premium science base – Global opportunities if a strategic fit – Building global leaders in an international industry
Focus areas
– Innovative technology with potential for dramatic efficacy in high unmet needs – Specialists in gene therapy, cell therapy and advanced diagnostics
Premium networks and access – Aligned with two of the premium charitable funders in the space: – The Wellcome Trust, 2nd largest private funder of medical research globally – CRUK, the world’s leading cancer charity – Largest investor in CRT Pioneer Fund; exclusive pipeline agreement with CRUK A connected and experienced team – A leading Partnership group with deep global networks – Strong reputation in key focus areas (eg. gene therapy) attracting a pipeline of premium new opportunities Diversity, quality and strength of network demonstrated by current portfolio
Deep global networks across a highly experienced partnership group
37
Rigorous approach to identifying and verifying scientific and commercial potential
38
– High conviction approach: intentionally lower volume and more intensive – Hundreds of potential opportunities per year – Initial vetting through Syncona’s ‘3 core focus areas’ – c.20 detailed projects completed per annum – Expert scientific knowledge and deep specific expertise in regulatory, supply chain, manufacturing, product launch, clinical development, Intellectual Property – Partnership approach starts early: creating value pre-investment
⎻ Hypothesis formation ⎻ Testing and analysis of data ⎻ Extrapolation to clinical concept
Scientific
⎻ Patient population and treatment paradigm ⎻ Pricing/ reimbursement landscape ⎻ Competition and exclusivity/IP
Commercialisation
⎻ Pre-clinical experiments ⎻ Manufacturing considerations ⎻ Regulatory pathways ⎻ Trial size and design
Development